
Monthly Injectable Buprenorphine Cuts Relapse Risk by Up to 8 Times, New Studies Show
Real-world evidence demonstrates extended-release buprenorphine significantly reduces opioid relapse, bloodstream infections, and healthcare utilization compared to daily oral formulations.























































































































































































